FDA approves ZymoGenetics' rThrombin

ZymoGenetics has received FDA approval to market rThrombin, a surgical blood clotting product. The drug is a recombinant form of human thrombin; previous treatments were derived from human or animal blood. ZymoGenetics says that production of the new drug doesn't depend on the availability of animal or human blood and can therefore be scaled-up to meet market demand.

The drug, to be sold under the name Recothrom, was acquired by Bayer last year in a $198 million deal. The FDA approval triggers a $40 million milestone payment to ZymoGenetics.

- see this release for more

ALSO: Check out the 17 new drugs that received FDA approval last year. List

Suggested Articles

Levo Therapeutics’ lead program did not beat placebo in a phase 3 study of Prader-Willi syndrome, a genetic disorder that causes insatiable hunger.

Denali is partnering with Biogen on its Parkinson's disease program, netting a $560 million upfront fee and a $465 million investment.

In the first half of 2020, the regenerative medicine sector raised $10.7 billion, more than the total it raised in 2019.